1. Home
  2. BLND vs IVA Comparison

BLND vs IVA Comparison

Compare BLND & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLND
  • IVA
  • Stock Information
  • Founded
  • BLND 2012
  • IVA 2011
  • Country
  • BLND United States
  • IVA France
  • Employees
  • BLND N/A
  • IVA N/A
  • Industry
  • BLND EDP Services
  • IVA Biotechnology: Pharmaceutical Preparations
  • Sector
  • BLND Technology
  • IVA Health Care
  • Exchange
  • BLND Nasdaq
  • IVA Nasdaq
  • Market Cap
  • BLND 894.7M
  • IVA 769.0M
  • IPO Year
  • BLND 2021
  • IVA 2020
  • Fundamental
  • Price
  • BLND $3.00
  • IVA $3.97
  • Analyst Decision
  • BLND Buy
  • IVA Strong Buy
  • Analyst Count
  • BLND 6
  • IVA 8
  • Target Price
  • BLND $4.80
  • IVA $16.13
  • AVG Volume (30 Days)
  • BLND 3.7M
  • IVA 482.1K
  • Earning Date
  • BLND 11-06-2025
  • IVA 09-29-2025
  • Dividend Yield
  • BLND N/A
  • IVA N/A
  • EPS Growth
  • BLND N/A
  • IVA N/A
  • EPS
  • BLND N/A
  • IVA N/A
  • Revenue
  • BLND $167,532,000.00
  • IVA $19,929,536.00
  • Revenue This Year
  • BLND N/A
  • IVA N/A
  • Revenue Next Year
  • BLND $27.27
  • IVA N/A
  • P/E Ratio
  • BLND N/A
  • IVA N/A
  • Revenue Growth
  • BLND 37.61
  • IVA N/A
  • 52 Week Low
  • BLND $2.50
  • IVA $2.11
  • 52 Week High
  • BLND $5.53
  • IVA $7.98
  • Technical
  • Relative Strength Index (RSI)
  • BLND 40.10
  • IVA 41.35
  • Support Level
  • BLND $2.97
  • IVA $3.55
  • Resistance Level
  • BLND $3.16
  • IVA $4.10
  • Average True Range (ATR)
  • BLND 0.19
  • IVA 0.57
  • MACD
  • BLND -0.01
  • IVA -0.05
  • Stochastic Oscillator
  • BLND 44.39
  • IVA 9.02

About BLND Blend Labs Inc.

Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: